Using the agreed starting and stopping criteria, sorafenib can be made available within NHS Wales for maintenance treatment following allogeneic stem cell transplantation for acute myeloid leukaemia associated with a FLT3 ITD mutation.

The risks and benefits of the off-label use of sorafenib for this indication should be clearly stated and discussed with the patient to allow informed consent.

In February 2022 OWMAG recommended this treatment in NHS Wales, in May 2023 there was a review of the recommendation. OWMAG found nothing new that affects the original decision.

Next review: this decision will be reviewed again after three years or earlier if new evidence becomes available.